Therapy Directory

Fulvestrant clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Fulvestrant as a study intervention. Browse Fulvestrant recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

294

Shown on this page

Local indexed summaries

110

Local recruiting

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Showing 1–12 of 294 matching trials for Fulvestrant.

Live ClinicalTrials.gov results.

Top conditions

Breast Cancer 37 Metastatic Breast Cancer 20 Advanced Breast Cancer 12 HER2-negative Breast Cancer 8 Breast Neoplasms 7 Advanced Solid Tumor 6

Top sponsors

Pfizer 9 Hoffmann-La Roche 8 Eli Lilly and Company 7 AstraZeneca 6 Novartis Pharmaceuticals 5 BeOne Medicines 3

Top locations

Boston, Massachusetts 48 Houston, Texas 48 New York, New York 42 Nashville, Tennessee 40 Los Angeles, California 35 San Antonio, Texas 29

Live official records

Open in full search

Conditions: HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions: palbociclib, trastuzumab, pertuzumab, letrozole, Anastrozole, Exemestane, Fulvestrant; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 35
States / cities: San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more

Conditions: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions: PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide, Giredestrant, Tamoxifen; Drug · Combination Product · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 14
States / cities: Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more

Conditions: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Interventions: PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060, PF-07850327, ARV-471, vepdegestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 22
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 11 more

Conditions: Breast Cancer, Diabetes Type II
Interventions: Inavolisib, Fulvestrant, Palbociclib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Grand Island, Nebraska + 4 more

Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions: BG-68501, Fulvestrant, BGB-43395; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more

Conditions: Advanced HR+/HER2- Breast Cancer
Interventions: IEV407, Fulvestrant, Letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: New Haven, Connecticut • Kansas City, Kansas • Dallas, Texas

Conditions: Breast Cancer
Interventions: PF-07248144, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 215
States / cities: Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 150 more

Conditions: Metastatic Breast Cancer
Interventions: Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 16
States / cities: Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 13 more

Conditions: Advanced Solid Tumors
Interventions: ATX-898, ATX-898, fulvestrant, ribociclib; Drug
Lead sponsor: Antares Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Fort Worth, Texas • Houston, Texas • San Antonio, Texas + 2 more

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
Interventions: Trastuzumab deruxtecan, Trastuzumab, Pertuzumab, Endocrine Therapy, Palbociclib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Columbia, Maryland • Las Vegas, Nevada • Nashville, Tennessee + 2 more

Conditions: Metastatic Breast Cancer
Interventions: Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Gilbert, Arizona • Burbank, California • Corona, California + 17 more

About this Fulvestrant clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Fulvestrant as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Fulvestrant.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Fulvestrant clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Live official records

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Roll-over Study to Allow Continued Access to Ribociclib

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

About this Fulvestrant clinical trials directory page